In Vitro Technologies :: Products

Permits and Restrictions	View Permits View Restrictions
Organism	Homo sapiens, human
Components	ATCC HTB-23 MDA-MB-134-VIATCC CRL-2066 DMS 114ATCC CCL-235 SW837ATCC CCL-246 KG-1ATCC CCL-247 HCT116ATCC CRL-5974 SNU-16ATCC HTB-103 KATO IIIATCC CRL-1739 AGS
Applications	This validated panel is composed of 8 select human cancer cell lines carrying various degrees of FGFR1 and FGFR2 amplification, and is useful for FGFR pathway research and for anti-cancer drug discovery.
Biosafety Level	2 [Cells contain Parainfluenza virus type 5] Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Comments	Fibroblast Growth Factor Receptors (FGFRs), are transmembrane tyrosine kinase receptors that induce intracellular tyrosine kinase activity when bound to Fibroblast Growth Factor. FGFR plays crucial roles in development and cell growth. Upregulation of the FGF/FGFR signaling pathway leads to induction of mitogenic and survival signals, as well as promoting epithelial-mesenchymal transition, invasion and tumor angiogenesis. Amplification or activation of FGFR1 and FGFR2 genes has been linked to several cancer types such as lung cancer, breast cancer and gastric cancer. The FGFR genetic alteration cell panel (ATCC TCP-1034) is composed of eight selected human tumor cell lines from common cancer types that carry various gene copy number amplification within the FGFR1 or FGFR2 genes. The FGFR1 or FGFR2 status of each cell line has been validated by ATCC. This panel is useful for FGFR pathway research and FGFR inhibitors anti-cancer drug discovery.
Product Format	8 cryopreserved cell lines
Storage Conditions	liquid nitrogen vapor phase (less than -130°C) only

Permits	These permits may be required for shipping this product to Australia: License agreement required for commercial customer uses. DAFF Import Permit formerly known as AQIS Import Permit must be obtained and a copy of the permit must be sent to ATCC in advance of shipment.
Basic Documentation	Product Sheet Certificate of Analysis SDS
Other Documentation	Recommended Culture Conditions Genetic Alteration Panels - Brochure
Restrictions	Unless the Purchaser has a separate license agreement with The University of Texas M. D. Anderson Cancer Center (“Institution”), the ATCC Material is subject to the following restrictions: The ATCC Material (and any Modifications, Unmodified Derivatives and/or Progeny thereof) may not be used (1) for commercial purposes or Commercial Use by any Purchaser, or (2) by for-profit or commercial entities for any purpose, provided, however, that ATCC Material that is purchased from ATCC as deoxyribonucleic acid and/or ribonucleic acid or nucleotide chains of any length (hereinafter, “Nucleic Acids”) may be used for internal research purposes by any Purchaser of Nucleic Acids; Purchaser may not transfer ATCC Materials, Modifications, Unmodified Derivatives, or Progeny to any for-profit entity or commercial entity; and Purchaser may not use ATCC Materials (or any Modifications, Unmodified Derivatives and/or Progeny thereof) in connection with any research, collaboration or other activities involving a third party that is a commercial entity or for-profit entity. The restrictions set forth above are in addition to the restrictions set forth in the ATCC Material Transfer Agreement. Capitalized terms have the meanings set forth in the ATCC Material Transfer Agreement unless otherwise indicated above. For instructions on how to obtain a license from Institution, please contact Dustin J. Romine, M.A. at the Institution Office of Technology Commercialization via email at dromine@mdanderson.org. Purchaser acknowledges and agrees that ATCC will send Purchaser’s contact information and order details to Institution’s Office of Technology Commercialization.

E: care@invitro.com.au
P: 1300 552 003

Request a quote or demo
Contact a Specialist